In the phase 1 dose-escalation study NCT02298959, anti-angiogenesis agent ziv-aflibercept (recombinant fusion protein containing VEGF-binding domains developed based on VEGFR1/2) combined with anti-PD-1 antibody pembrolizumab exhibited potent antitumor activity in solid tumors (including ovarian cancer, renal cell carcinoma, colorectal cancer, and melanoma) with manageable safety profile (144). This evidence concerns the gene VEGFA and ovarian carcinoma.